Mirum Pharmaceuticals, Inc.

NasdaqGM:MIRM Stock Report

Market Cap: US$6.2b

Mirum Pharmaceuticals Management

Management criteria checks 3/4

Mirum Pharmaceuticals' CEO is Chris Peetz, appointed in Mar 2019, has a tenure of 6.92 years. total yearly compensation is $6.60M, comprised of 11.1% salary and 88.9% bonuses, including company stock and options. directly owns 0.55% of the company’s shares, worth $34.14M. The average tenure of the management team and the board of directors is 4.1 years and 6.6 years respectively.

Key information

Chris Peetz

Chief executive officer

US$6.6m

Total compensation

CEO salary percentage11.06%
CEO tenure6.9yrs
CEO ownership0.6%
Management average tenure4.1yrs
Board average tenure6.6yrs

Recent management updates

Recent updates

Subdued Growth No Barrier To Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) With Shares Advancing 25%

Jan 28
Subdued Growth No Barrier To Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) With Shares Advancing 25%

Mirum: Maintaining Buy Rating On VOLIXIBAT PSC Treatment Data Q2 2026

Dec 22

Mirum Pharmaceuticals (NASDAQ:MIRM) Is Carrying A Fair Bit Of Debt

Oct 16
Mirum Pharmaceuticals (NASDAQ:MIRM) Is Carrying A Fair Bit Of Debt

Analysts Just Shipped A Substantial Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates

Aug 11
Analysts Just Shipped A Substantial Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates
User avatar

FDA And Japanese Approvals Will Open New Markets

Strong revenue growth and recent regulatory approvals are set to expand market reach and positively impact future revenues.

Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like

Mar 24

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Looks Inexpensive But Perhaps Not Attractive Enough

Mar 21
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Looks Inexpensive But Perhaps Not Attractive Enough

Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3)

Jan 08

Mirum Pharma: Buy At Dips For Volixibat Potential

Dec 25

Mirum Pharmaceuticals: Intriguing, But Wait For Volixibat Data Makes Me Bearish

Oct 04

Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition

Jul 17

Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value

Apr 22

Mirum Pharmaceuticals: Advancing On Several Key Fronts

Mar 05

CEO Compensation Analysis

How has Chris Peetz's remuneration changed compared to Mirum Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$41m

Jun 30 2025n/an/a

-US$59m

Mar 31 2025n/an/a

-US$77m

Dec 31 2024US$7mUS$730k

-US$88m

Sep 30 2024n/an/a

-US$100m

Jun 30 2024n/an/a

-US$109m

Mar 31 2024n/an/a

-US$159m

Dec 31 2023US$6mUS$660k

-US$163m

Sep 30 2023n/an/a

-US$164m

Jun 30 2023n/an/a

-US$176m

Mar 31 2023n/an/a

-US$129m

Dec 31 2022US$4mUS$624k

-US$136m

Sep 30 2022n/an/a

-US$42m

Jun 30 2022n/an/a

-US$53m

Mar 31 2022n/an/a

-US$70m

Dec 31 2021US$4mUS$600k

-US$84m

Sep 30 2021n/an/a

-US$179m

Jun 30 2021n/an/a

-US$153m

Mar 31 2021n/an/a

-US$132m

Dec 31 2020US$3mUS$512k

-US$103m

Sep 30 2020n/an/a

-US$84m

Jun 30 2020n/an/a

-US$78m

Mar 31 2020n/an/a

-US$68m

Dec 31 2019US$6mUS$458k

-US$53m

Compensation vs Market: Chris's total compensation ($USD6.60M) is about average for companies of similar size in the US market ($USD7.70M).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.

CEO

Chris Peetz (46 yo)

6.9yrs
Tenure
US$6,598,551
Compensation

Mr. Christopher Peetz, also known as Chris, was Independent Director of Alpine Immune Sciences, Inc. from April 24, 2018. He joined the Alpine Immune Sciences, Inc. on April 24, 2018. He is CEO & Director...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Peetz
CEO & Director6.9yrsUS$6.60m0.55%
$ 34.1m
Peter Radovich
COO & President5.8yrsUS$3.34m0.026%
$ 1.6m
Eric Bjerkholt
Chief Financial Officer2.4yrsUS$2.01m0.073%
$ 4.5m
Joanne M. Quan
Chief Medical Officer2.1yrsUS$3.59m0.021%
$ 1.3m
Jean-Luc Girardet
Chief Technical Officerno datano datano data
Andrew McKibben
Senior Vice Presidentno datano datano data
Douglas Sheehy
Chief Legal Officerless than a yearno datano data
Meredith Kiernan
Senior Director of Global Corporate Communicationsno datano datano data
Erin Campany
Chief People Officer7.1yrsno datano data
Lara Longpre
Chief Development Officer7.2yrsUS$1.51mno data
Vinita Kumar
Senior Vice President of Quality4.1yrsno datano data
Nancy Shulman
Executive Vice President of Clinicalless than a yearno datano data
4.1yrs
Average Tenure
58yo
Average Age

Experienced Management: MIRM's management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christopher Peetz
CEO & Director7.1yrsUS$6.60m0.55%
$ 34.1m
Patrick Heron
Independent Director7.3yrsUS$358.51k0.0095%
$ 587.7k
Laura Brege
Independent Director6.6yrsUS$383.51k0.026%
$ 1.6m
Michael Grey
Independent Non-Executive Chairman of the Board6.9yrsUS$408.51k0.47%
$ 28.9m
Laurent Fischer
Independent Director6.7yrsUS$378.51k0.011%
$ 695.8k
Timothy Walbert
Independent Director2.8yrsUS$363.51k0.0095%
$ 587.7k
Sona Saira Ramasastry
Independent Director3.7yrsUS$368.51kno data
William Fairey
Independent Director4.5yrsUS$368.51k0.0042%
$ 258.1k
Lon Cardon
Independent Director3.3yrsUS$353.51k0.0095%
$ 587.7k
6.6yrs
Average Tenure
59yo
Average Age

Experienced Board: MIRM's board of directors are considered experienced (6.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/17 14:08
End of Day Share Price 2026/02/13 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Mirum Pharmaceuticals, Inc. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Joshua SchimmerCantor Fitzgerald & Co.
David LebowitzCitigroup Inc